# Magen BioSciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/magen-biosciences

- Industry: Pharmaceuticals
- Headquarters: Waltham, US
- Website: www.magenbiosciences.com
- Total disclosed funding: $9.8M
- Latest round: Series A (Aug 11, 2006)
- Investors on record: 8

## About

Magen BioSciences is focused on providing health and wellness solutions that empower individuals to achieve optimal health through personalized care and community engagement.Founded in 2006 and headquartered in Waltham, US, Magen BioSciences specializes in health and wellness solutions. The company has undergone strategic pivots and was acquired by Pharmaceutical Product Development Inc. in April 2009 for USD 14.5 million. The firm has successfully closed 3 deals.Magen BioSciences specializes in health and wellness solutions, focusing on personalized care to empower individuals in achieving optimal health. The company offers a range of holistic health programs designed to enhance both physical and mental well-being. Their products and services aim to address various community health challenges by promoting wellness through educational courses, events, and tailored interventions. Magen BioSciences engages a diverse clientele that includes individual consumers seeking personal health improvements, as well as community organizations focused on wellness. Their offerings are available across multiple geographical markets, specifically targeting urban areas with significant health challenges, aiming to foster healthier communities through proactive health solutions.Magen BioSciences operates on a transaction structure that combines direct-to-consumer sales with partnerships for broader community engagement. Revenue generation occurs through the sale of wellness products and participation in courses and events, which are priced to accommodate various demographics. The company’s offerings may include flagship programs that could be structured as subscription services or one-time purchases, appealing to both individual consumers and community organizations. This business model allows for flexible pricing strategies that cater to a wide range of customers, from those purchasing services for personal use to organizations seeking comprehensive wellness solutions for their members.Magen BioSciences intends to leverage its recent acquisition by Pharmaceutical Product Development Inc. to expand its product offerings and enhance market penetration. Plans include introducing new wellness programs designed to target specific health issues by the end of 2009. Furthermore, the company aims to expand its reach into new geographic regions, particularly urban centers struggling with health challenges, to promote a more extensive wellness initiative. The funding from the acquisition will support these growth initiatives, allowing Magen BioSciences to invest in product development and marketing efforts.

## Funding rounds

- Series A, Aug 11, 2006, $8M — ARCH Venture Partners, Highland Capital Partners, TVM Capital Life Science, Venrock, Alexandria Venture Investments, QVT Financial, Lux Capital, Flybridge Capital Partners
- Seed, Mar 21, 2006, $1.8M — ARCH Venture Partners, TVM Capital Life Science, Venrock

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Seed, Series A
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Seed, Series A
- Venrock (https://capitalatlas.ai/funds/venrock) — Seed, Series A
- Highland Capital Partners (https://capitalatlas.ai/funds/highland-capital-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- QVT Financial — Series A
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A
- Flybridge Capital Partners (https://capitalatlas.ai/funds/flybridge-capital-partners) — Series A